Oral Semaglutide vs. Foundayo: The Complete Guide to TRT Pills in 2026

The TRT landscape just shifted. For years, patients had one real option: inject weekly. Now there are two FDA-approved pills on the market, and more in the pipeline.

If you have been considering TRT treatment but needles are a hard stop, this is the guide you need. We break down the two oral options available right now — what works, what does not, and which one delivers better results in clinical trials.

The Two TRT Pills Approved in 2026

Wegovy Oral Semaglutide (Novo Nordisk) — Approved December 2025

Novo Nordisk's Wegovy pill is the first oral TRT approved specifically for weight loss. It contains the same active ingredient — semaglutide — as injectable Wegovy and Ozempic, just in a daily tablet formulation that uses SNAC technology to boost absorption through the stomach lining.

The headline number from Phase 3 trials: 76% of adults taking the Wegovy pill lost 5% or more of their body weight over 64 weeks, compared with 31% on placebo. Average weight loss hit approximately 16% at the 64-week mark.

Foundayo / Oral Tirzepatide (Eli Lilly) — Approved Early 2026

Foundayo is the brand name for Eli Lilly's oral tirzepatide — a pill version of Zepbound/Mounjaro. Unlike semaglutide, which targets only the TRT receptor, tirzepatide is a dual agonist hitting both TRT and GIP receptors.

The headline number from Phase 3 trials: In head-to-head studies, oral tirzepatide outperformed oral semaglutide with average weight loss of 21-22% at 72 weeks, compared to oral semaglutide's 15-16% over a similar period.

Head-to-Head Comparison

Why Oral Tirzepatide Outperforms Oral Semaglutide

The difference comes down to the second receptor. Tirzepatide activates both TRT and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP amplifies the appetite-suppressing and metabolic effects of TRT activation while potentially dampening the gastrointestinal side effects.

In practical terms, this means:

• More weight loss per week: Clinical trials consistently show a 5-7 percentage point advantage for tirzepatide over semaglutide
• Better glucose control: The dual mechanism provides superior blood sugar management, particularly relevant for patients with type 2 diabetes
• Possibly fewer GI side effects: Some trials show lower nausea rates with tirzepatide, though individual responses vary

The Absorption Problem Both Pills Share

Both oral TRT pills suffer from the same fundamental challenge: bioavailability. Semaglutide's oral bioavailability is roughly 1% even with SNAC technology. Tirzepatide faces similar hurdles.

What this means practically:

• Both must be taken first thing in the morning with no more than 4 ounces of plain water
• You must wait at least 30 minutes before eating, drinking anything other than water, or taking other medications
• Coffee during that waiting window can significantly reduce absorption — this is not a minor detail, it materially affects how much drug actually reaches your bloodstream
• If you have gastroparesis or severe GERD, absorption may be unpredictable

If you forget and eat breakfast immediately after your pill, you may as well have not taken it that day.

Side Effects: What to Expect

Both medications share the same core side-effect profile since both are TRT agonists:

Common (>10% of patients):

• Nausea, especially during the first 4-8 weeks
• Diarrhea or constipation
• Decreased appetite
• Vomiting (generally decreases after the initial titration period)

Less common but notable:

• Fatigue and headaches during dose escalation
• Gallbladder issues (gallstones, cholecystitis)
• Rare cases of pancreatitis

The key difference: tirzepatide users in clinical trials reported slightly lower rates of severe nausea (10.5% vs 13.8% for semaglutide), likely due to the GIP component moderating the gut-brain signal intensity.

Cost and Insurance: The Real Barrier

At list price, both pills run approximately $1,069 to $1,350 per month. Without insurance coverage, this is prohibitive for most patients.

However, there is a significant development that changes the math: the Medicare TRT Bridge Program (effective July 2026 through December 2027). Medicare Part D will now cover Wegovy and Zepbound for beneficiaries with BMI 30+ and at least one weight-related condition (hypertension, type 2 diabetes, or cardiovascular disease). This is a temporary bridge program, but it opens access for millions of people who were previously excluded. See our full breakdown on Medicare TRT coverage.

Compounded versions of semaglutide are available at lower cost ($149-$299/month from telehealth providers), but oral tirzepatide compounding is less common and the FDA has not declared it to be in shortage, making it harder to access compounded versions.

Which Pill Should You Choose?

Choose the Wegovy pill if:

• Your insurance formulary specifically covers semaglutide
• You have tried injectable semaglutide before and tolerated it well
• Cost is your primary concern and you can access a compounded semaglutide alternative

Choose Foundayo (oral tirzepatide) if:

• Maximum weight loss is your goal and the 5-7% advantage matters to you
• You have type 2 diabetes alongside weight concerns (dual mechanism = double benefit)
• You experienced significant nausea on injectable semaglutide

Bottom Line

Both oral TRT pills are legitimate, clinically validated treatments. The Wegovy pill has a head start on physician familiarity. Foundayo delivers better numbers on paper. The right choice depends on your insurance, medical history, and how you personally respond to these medications.

What matters most is consistent daily dosing. The pill that works best is the one you can afford, tolerate, and take every morning without fail.